Week In Review: Investors Embrace Future Of Biologics Drugs In Samsung Biologics' $2 Billion IPO
November 12, 2016 at 13:42 PM EST
Samsung Biologics completed a $2 billion IPO in South Korea at an $8 billion valuation. Samsung Biologics will use the proceeds to complete construction of its third manufacturing facility, a $740 million project.
